✦ LIBER ✦

Leiomyosarcoma of the kidney: Report of a patient with favorable response to doxorubicin and cisplatin suspended in a lipid contrast medium and cyclophosphamide

✍ Scribed by Taniguchi, Hiroki ;Takahashi, Toshio ;Fujita, Yoshihiro ;Sakita, Masakazu ;Ogita, Shuhei ;Sawai, Kiyoshi ;Yamaguchi, Toshiharu ;Yokota, Takashi ;Nakagawa, Noboru ;Shimotsuma, Masataka ;Kondo, Shinji

Publisher: John Wiley and Sons
Year: 1987
Tongue: English
Weight: 419 KB
Volume: 15
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950150513

No coin nor oath required. For personal study only.

✦ Synopsis

A man who had unresectable leiomyosarcoma of the left kidney with skin and lung metastases was treated with intra-arterial infusion chemotherapy consisting of cisplatin and doxorubicin suspended in lipid contrast medium, lipiodol, and oral administration of cyclophosphamide. The tumor responded well to this treatment three times. He is alive and well in remission, the renal tumor decreased in size, and lung metastases became unclear more than 50 weeks after treatment was completed.

📜 SIMILAR VOLUMES

The addition of cisplatin to cyclophosph

The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients

✍ Thierry Urban; Claude Chastang; François-Xavier Lebas; Jean-Paul Duhamel; Guy Ad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel

A metastatic neuroendocrine anaplastic s

A metastatic neuroendocrine anaplastic small cell tumor in a patient with multiple endocrine neoplasia type 1 syndrome. Assessment of disease status and response to doxorubicin, cyclophosphamide, etoposide chemotherapy through scintigraphic imaging with 111in-pentetreotide

✍ Kenneth J. O'Byrne; Michael G. Goggins; Dermot P. Kelleher; Donald G. Weir; Geor 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 635 KB

Extrapulmonary small cell and small cell neuroendocrine tumors of unknown primary site are, in general, aggressive neoplasms with a short median survival. Like small cell lung cancer (SCLC), they often are responsive to chemotherapy and radiotherapy. Small cell lung cancer and well differentiated ne

Complete hematologic and cytogenetic res

Complete hematologic and cytogenetic response to 2-amino-9-β-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogeneous leukemia in T-cell blastic phase : A case report and review of the literature

✍ Alvaro Aguayo; Jorge E. Cortes; Hagop M. Kantarjian; Miloslav Beran; Varsha Gand 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## BACKGROUND. T-cell lymphoid blastic phase (BP) transformation is rare in chronic myelogenous leukemia (CML). 2-amino-9-␤-D-arabinosyl-6-methoxy-9H-guanine (GW506U78), a prodrug of arabinosylguanine (ara-G), is effective in T-cell leukemias. ## METHODS. The authors present a case of a 48-year

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views